People: G1 Therapeutics Inc (GTHX.OQ)
16 Aug 2019
Sir Andrew Philip Witty is an Independent Director of G1 Therapeutics Inc. Mr. Witty has served as a member of our Board of Directors since July 2017. Sir Andrew served as Chancellor of the University of Nottingham in England from 2013 to 2018, and has served as Chief Executive Officer at Optum, a global health services company and part of UnitedHealth Group, since 2018. Sir Andrew retired as Chief Executive Officer of GlaxoSmithKline in March 2017, a position he held since May 2008. Sir Andrew joined GlaxoSmithKline in 1985 and served in a variety of roles in the U.K. and overseas, including South Africa, the U.S. and Singapore. Sir Andrew has served in numerous advisory roles to governments around the world including South Africa; Guangzhou, China; and the U.K., where he was a member of the Prime Minister’s Business Advisory Group from 2010 until 2015. In 2012, Sir Andrew was awarded a knighthood for services to the U.K. pharmaceutical industry. In May 2016, Sir Andrew became a visiting professor at the Institute of Global Health Innovation at Imperial College, London. He has a joint honors B.A. in economics from the University of Nottingham, England. We believe that Sir Andrew is qualified to serve as a member of our Board of Directors based on his extensive experience in the pharmaceutical industry, including serving as a chief executive officer of a global pharmaceutical company.
|Total Annual Compensation, USD||300,973|
|Restricted Stock Awards, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||--|
|Fiscal Year Total, USD||300,973|